HomeCompareWSBCP vs ABBV

WSBCP vs ABBV: Dividend Comparison 2026

WSBCP yields 6.75% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $34.6K in total portfolio value
10 years
WSBCP
WSBCP
● Live price
6.75%
Share price
$24.99
Annual div
$1.69
5Y div CAGR
19.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$67.8K
Annual income
$11,714.58
Full WSBCP calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — WSBCP vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodWSBCPABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, WSBCP + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
WSBCP pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

WSBCP
Annual income on $10K today (after 15% tax)
$573.99/yr
After 10yr DRIP, annual income (after tax)
$9,957.39/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $11,098.61/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of WSBCP + ABBV for your $10,000?

WSBCP: 50%ABBV: 50%
100% ABBV50/50100% WSBCP
Portfolio after 10yr
$85.0K
Annual income
$18,243.17/yr
Blended yield
21.45%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

WSBCP
Analyst Ratings
3
Buy
8
Hold
Consensus: Hold
Altman Z
0.4
Piotroski
7/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

WSBCP buys
0
ABBV buys
0
No recent congressional trades found for WSBCP or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricWSBCPABBV
Forward yield6.75%3.06%
Annual dividend / share$1.69$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR19.8%40.6%
Portfolio after 10y$67.8K$102.3K
Annual income after 10y$11,714.58$24,771.77
Total dividends collected$40.6K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: WSBCP vs ABBV ($10,000, DRIP)

YearWSBCP PortfolioWSBCP Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,509$808.98$11,550$430.00$41.00ABBV
2$13,357$1,042.44$13,472$627.96$115.00ABBV
3$15,647$1,354.55$15,906$926.08$259.00ABBV
4$18,518$1,776.55$19,071$1,382.55$553.00ABBV
5$22,169$2,354.16$23,302$2,095.81$1.1KABBV
6$26,876$3,155.35$29,150$3,237.93$2.3KABBV
7$33,040$4,282.95$37,536$5,121.41$4.5KABBV
8$41,248$5,895.15$50,079$8,338.38$8.8KABBV
9$52,376$8,240.04$69,753$14,065.80$17.4KABBV
10$67,757$11,714.58$102,337$24,771.77$34.6KABBV

WSBCP vs ABBV: Complete Analysis 2026

WSBCPStock

WesBanco, Inc. operates as the bank holding company for WesBanco Bank, Inc. that provides retail banking, corporate banking, personal and corporate trust, brokerage, and mortgage banking and insurance services. It operates in two segments, Community Banking, and Trust and Investment Services. The company offers commercial demand, individual demand, and time deposit accounts; money market accounts; interest bearing and non-interest bearing demand deposits, as well as savings deposits; and certificates of deposit. It also provides commercial real estate loans; commercial and industrial loans; residential real estate loans, including loans to purchase, construct, or refinance borrower's home; home equity lines of credit; installment loans to finance the purchase of automobiles, trucks, motorcycles, boats, and other recreational vehicles, as well as home equity installment loans, unsecured home improvement loans, and revolving lines of credit; and commercial, mortgage, and individual installment loans. In addition, the company offers trust and investment services, as well as various investment products comprising mutual funds and annuities; and securities brokerage services. Further, WesBanco, Inc., through its non-banking subsidiaries, acts as an agency that specializes in property, casualty, life, and title insurance, as well as benefit plan sales and administration to personal and commercial clients; provides broker dealer and discount brokerage services; holds investment securities and loans; and holds and leases commercial real estate properties, as well as acts as an investment adviser to a family of mutual funds. As of December 31, 2021, it operated 206 branches and 203 ATMs in West Virginia, Ohio, western Pennsylvania, Kentucky, southern Indiana, and Maryland, as well as seven loan production offices in West Virginia, Ohio, western Pennsylvania, Maryland, and northern Virginia. WesBanco, Inc. was founded in 1870 and is headquartered in Wheeling, West Virginia.

Full WSBCP Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this WSBCP vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

WSBCP vs SCHDWSBCP vs JEPIWSBCP vs OWSBCP vs KOWSBCP vs MAINWSBCP vs JNJWSBCP vs MRKWSBCP vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.